

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

Date of Report: May 4, 2015  
Commission File Number: 001-36891

**Collectis S.A.**

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Title</u></b>
99.1	Press release, dated May 4, 2015.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELLECTIS S.A.**  
(Registrant)

May 4, 2015

By: /s/ André Choulika  
André Choulika  
Chief Executive Officer

**Collectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary**

PARIS--(BUSINESS WIRE)--May 4, 2015--Regulatory News:

Collectis S.A. (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS) a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that it has changed the name of its subsidiary, Collectis plant sciences, Inc. to Calyxt, Inc.

The name change is part of Collectis' effort to further distinguish the parent company's focus from that of its subsidiary. Gene editing is the common base of the two companies: it is used by Collectis in the development of new and innovative product candidates for treatment of cancers, and by Calyxt in the development of improved crops for consumers with healthier characteristics.

The goal of the name change is to leverage the strengths of both Collectis and Calyxt brand identities.

To find out more about Calyxt, please visit [www.calyxt.com](http://www.calyxt.com)

**About Collectis**

Collectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com)

**CONTACT:****Media**

Jennifer Moore, 917-580-1088

Director of Communications

[contact@collectis-plantsciences.com](mailto:contact@collectis-plantsciences.com)

or

**BMC Communications**

Brad Miles, 646-513-3125

[bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)

or

**IR contacts**

Simon Harnest, 646-385-9008

VP Finance and Investor Relations

[simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)